Examining the Effects of In Vitro Co-Culture of Equine Adipose-Derived Mesenchymal Stem Cells With Tendon Proper and Peritenon Cells.
Authors: Pechanec Monica Y, Beall Jessica M, Katzman Scott, Maga Elizabeth A, Mienaltowski Michael J
Journal: Journal of equine veterinary science
Summary
# Editorial Summary Tendon injuries remain a significant challenge in equine practice, with limited regenerative capacity making them a leading cause of career-ending lameness, yet the molecular mechanisms underlying mesenchymal stem cell (MSC) therapy remain poorly understood. Researchers co-cultured equine adipose-derived MSCs with both intrinsic tendon cells (from the tendon proper) and extrinsic cells (from the peritenon) to investigate cellular cross-talk, measuring gene expression profiles at 48 and 120 hours alongside cell proliferation rates over five days. MSCs promoted a generally favourable tenogenic response in both cell populations, with particularly robust increases in lysyl oxidase (LOX), scleraxis (SCX), and mohawk (MKX) expression within 48 hours—genes critical for tendon maturation, collagen crosslinking, and mechanical properties—though notably, type I collagen (COL1A1) expression decreased. Peritenon cells showed additional benefits including reduced expression of proteoglycans (biglycan and CSPG4) associated with inflammatory activity, whilst tendon proper cells demonstrated improved overall proliferation when exposed to MSCs. These findings suggest that injected adipose-derived MSCs do engage constructively with resident tendon populations to drive tenogenic gene expression and metabolic activity, though the paradoxical reduction in COL1A1 warrants further investigation to clarify whether this reflects a temporary phase in the healing cascade or a limitation of the therapeutic approach that practitioners should monitor clinically.
Read the full abstract on PubMed
Practical Takeaways
- •Adipose-derived MSC injections appear to stimulate tenogenic gene expression in tendon cells in vitro, suggesting potential molecular benefits for tendon repair therapy
- •The decreased type I collagen expression warrants further investigation before assuming clinical benefit, as collagen quality and quantity are critical for functional tendon healing
- •In vitro results are promising but long-term efficacy and clinical outcomes in vivo remain to be determined before relying on MSC therapy as primary treatment
Key Findings
- •MSCs co-cultured with tendon proper or peritenon cells demonstrated altered gene expression trending toward tenogenic phenotype, except for decreased type I collagen (COL1A1)
- •Peritenon cells co-cultured with MSCs showed significant increases in lysyl oxidase (LOX), mohawk (MKX), and scleraxis (SCX) within 48 hours
- •Tendon proper cells co-cultured with MSCs exhibited improved cell proliferation overall
- •Peritenon cells showed significant decreases in biglycan (BGN) and CSPG4 at 48 and 120 hours when co-cultured with MSCs